

High Altitude Illness and Adaptation: Hints from Proteomics

Kumari Smita¹, MA Qadar Pasha² and SK Jain^{1*}

¹Department of Biotechnology, Jamia Hamdard, New Delhi, India

²Institute of Genomics and Integrative Biology, Mall Road, Delhi, India

Abstract

Proteomics has been successfully applied to many biomedical fields. Among these, high altitude (HA) proteomics has attracted researchers in past few years. Adaptation to hypobaric hypoxia (HH) is necessary for humans under several environmental, physiological and pathological situations. High altitude environmental challenges are major concern for sojourners, soldiers and mountaineers not only during their initial days of induction to the hypoxic environment but during long term residency. Hypoxia triggers oxidative stress and damage to proteins, lipids and DNA. This condition can occur due to environmental factors (altitude), toxicity or diseases. Sometimes body overcome the stress caused by hypoxia through unique process of self recovery and adaptation. Identifying the molecular variables playing key roles in this process are of prime importance in understanding the mechanisms for counteracting the negative effects oxygen deprivation that may lead to several diseases. Proteins play vital role in these physiological conditions and can be considered as molecular signature for altitude adaptation. Several proteins have been identified and categorised on the basis of their role in hypoxia and HA adaptation. Recent advances in proteomics have opened new vistas to understand the functional aspect of differential expression of proteins. Linking existing proteins together, finding newer proteins and their functional analysis can provide better understanding of the physiological mechanism underlying adaptation to hypoxia. New information coming from the analysis of the novel proteins offers opportunity to further analyse the cellular responses to HH.

Keywords: Hypobaric hypoxia; Gene regulation; Proteomics; Hypoxia associated proteins; Two-dimensional electrophoresis; Mass spectrometry

Introduction

The human habitation includes diverse range of environments; some of the most extreme of these environments are found at high altitudes. The three major HA regions with long-term resident populations are the Himalayan region/Tibetan Plateau (Tibetans, Ladakhi, and Sherpas), the Andes (Quechua and Ayamara), and Northern Africa (Ethiopians) [1-3]. Residents of these regions descend from a long line of highland ancestors who have lived there for generations despite the physiological challenges associated with chronic oxygen deprivation. The study of indigenous HA residents therefore, provide the opportunity to identify molecular markers that might have played a role in hypoxic adaptation. Hypoxia is a pathophysiological condition which occurs due to lower of circulating oxygen levels in body [4,5]. Hypoxia can either be due to environment (HA), diseases or any kind of cellular toxicity. Despite having different underlying causes, all types of hypoxia have similar responses and consequences (Figure 1). Therefore in the present article we have discussed all those proteins whose expression has been found altered in either of the hypoxic conditions. More extensive studies are required for validating many of these proteins as HH markers. Hypobaric hypoxia can be divided into four different phases depending upon the altitude and corresponding reduced oxygen pressure (Table 1) [6-8]. Along with the altitude, the pressure of oxygen in atmosphere and level of saturation of haemoglobin in the blood of the residents play important role in determining the HH stage and degree of hypoxia [9]. Different degree of impaired functions of brain and other organs are noticed at various stages of HH [10]. These stages of hypoxia are important in understanding the major behavioural and physiological changes taking place at any particular stage [11].

Adaptation to altitude has two different aspects. The first refers to residents living at high altitude (high landers) and second refers to people who ascend to HA regions for relatively shorter period of time. The high landers do not show many complications because

they have adapted to these environments as the result of residing there for generations. People, who ascend to HA show variable degree of complications due to sudden lowering of oxygen content in atmosphere. The second aspect is of importance as it has clinical implications. Altitude sickness, some times leading to even fatal conditions, can develop in these people and therefore identification of molecular markers is required for development of either therapeutic or predictive medicines. High altitude pulmonary edema (HAPE), high altitude cerebral edema (HACE) is common diseases associated with HA.

Genomic changes during hypoxia have been extensively investigated; hypoxia-induced changes in the proteome have gained the interest of researchers in past few years. In past few years proteome-wide alterations during hypoxia have been reported through many proteomic studies [12-15] discussed in further sections.

The cellular responses to hypoxia are rather complex and characterized by alterations in expression of a number of stress related proteins, proteins associated with energy metabolism and angiogenic pathway proteins such as HSPs, NOS, GAPDH, VEGF, Erythropoietin [16-18]. Above all, the most protein which first comes when hypoxia is discussed is HIF (hypoxia inducible factor) which is a transcriptional regulator for most of the hypoxia related genes. It is well established that HIF-1, controls cellular oxygen homeostasis and plays a key role

***Corresponding author:** SK Jain, Department of Biotechnology, Jamia Hamdard, New Delhi, India, Tel: +91-11-26959688; Fax: +91-11-26059663; E-mail: skjain@jamiyahamdard.ac.in, sk608@rediffmail.com, smita.smart.03@gmail.com

Received July 22, 2014; **Accepted** November 25, 2014; **Published** December 01, 2014

Citation: Smita K, Qadar Pasha MA, Jain SK (2014) High Altitude Illness and Adaptation: Hints from Proteomics. J Proteomics Bioinform S3: 004. doi:10.4172/jpb.S3-004

Copyright: © 2014 Smita K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Figure 1: Multiple physiological consequences and responses of hypoxia.

Stages	Altitude	PaO ₂ (mm Hg)	% saturation of haemoglobin
Indifferent	0-10,000 ft	100-60 mmHg	95-90%
Compensatory	10,000-15,000 ft	60-56 mmHg	90-80%
Disturbance stage	15,000-20,000 ft	45-35 mmHg	80-70%
Critical Stage	Above 20,000 ft	Less than 35 mmHg	70-60%

Table 1: Stages of hypoxia in aviation depending on altitude.

in energy metabolism [19]. HIFs represent the link between oxygen sensors and effectors at the cellular, local and systemic level [20]. An account of many altered proteins which can be perspective biomarkers has been presented in this article.

Proteomic analysis

The field of proteomics has grown many folds in post genomic era. It is now possible to identify and quantify large number of proteins using proteomic technologies. Proteomics is generally accepted as complementary to genetic profiling and comparative proteomic studies have been critical in identifying systems/ networks of proteins that contribute to disease progression. A significant aspect of proteomics lies in its ability to be quantitative and provide high-throughput strategy for global profiling of the changes in protein expression. An account of proteome coverage.

The protein expression levels are measured directly, rather than being inferred from abundance of the corresponding mRNAs that are imperfectly correlated to protein concentration due to variable rates of post-transcriptional modifications, differences in mRNA stability and translational efficiency [21,22]. The techniques commonly used for global analysis of protein expression include two-dimensional electrophoresis (2DE) in association with mass spectrometry (MS) [23], multidimensional chromatography coupled with tandem MS [24,25] and chip technologies coupled with either antigens or antibodies [26].

Two-dimensional gel electrophoresis coupled with matrix-assisted laser desorption/ ionization (MALDI) was the most extensively used approach for identifying and quantifying the changes in protein expression [27] during early proteomic era and will continue to be an integral part of proteomic research for the foreseeable future [28]. However, electro spray ionization spectroscopy coupled with MS [29]; multidimensional chromatography coupled to MS provides better separation power and extended concentration range to analyse complex samples than the one dimensional liquid chromatography coupled with

mass spectrometry [30]. Surface-enhanced laser desorption-ionization (SELDI) mass spectrometry is another technique that has been used and has solved the biomarker conundrum [31]. Different labelling methods such as iTRAQ (isobaric tags for relative and absolute quantitation), mTRAQ (mass differential tags for relative and absolute quantitation), TMT (tandem mass tags) and metabolic labeling/SILAC (stable isotope labeling of amino acids in cell culture) are being used currently for quantitative proteomics [32].

Exosomal proteome profiling (considered as potential multi-marker cellular phenotyping tool) is a recent advancement in proteomics [33]. Biofluids contain cell-secreted proteins in membrane-bound vesicles, termed exosomes. These small vesicles (50-100 nm in diameter), so far under-represented in body fluid proteome studies, originate from multivesicular bodies/endosomes and are being exploited in secretome proteomic research. The low abundant and membrane-bound proteins play important role in cell-to-cell communication. The protocols to isolate and purify exosomes and advances in mass spectrometry-based proteomics have helped in analysis of exosome content. Malignancy leads to hypoxia, resulting in release of exosomes from cancer cells. This may be responsible for malignant transformation of normal recipient cells and may result in malignant cell proliferation and migration [34-36].

The quantitative proteomics has been coupled with bioinformatics tools to develop the shotgun proteomics. Bioinformatics part in shotgun proteomics comprises different databases, search engines, softwares such as nsPecT, Mascot, OMSSA, SEQUEST, MyriMatch, X!Tandem, Trans-Proteomic Pipeline (TPP), MSBlender and PepArML [37]. The advanced proteomic tools, databases and bioinformatics software and their applicability [32] together has driven the field of proteomics. This approach is being applied for proteomic analysis of many of the known diseases to correlate proteins profile with pathogenesis and identify potential biomarkers. Proteome coverage for these biomarker candidates has been depicted in Figure 2. In addition to these serum/plasma proteins have been extensively utilized in biomarker studies and are equally important. A very recent plasma proteome study of HH induced rat model using 2 DE coupled with MALDI-TOF with peptide mass fingerprinting (PMF) and MS/MS analysis followed by database searching describes a number altered proteins like transthyretin, peroxiredoxin-2, Glutathione peroxidase3, Apolipoprotein A-I during HH [38].




Figure 2: Schematic of the availability of different cellular proteins. Cytoplasmic, nuclear and secreted proteins are highly available proteins whereas membrane bound are less available as membrane proteins are difficult to isolate due in part to the high degree of hydrophobicity. DNA-bound proteins are also more difficult to analyze than soluble nuclear protein fractions. In addition serum/plasma is also rich in proteins.

Overall steps involved in proteomic analysis of protein from different source like tissue, serum/plasma is depicted in Figure 3 (flow diagram).

Proteomics of hypoxia

By using the different proteomic approaches (above mentioned), it has been possible to analyze differentially expressed proteins and assess the changes in metabolic pathways in response to hypoxia at the tissue level. Comparative analysis of hypoxia related proteins suggests that hypoxia up-regulates or down-regulates a number of proteins in cell type or tissue dependent manner. Major consequences and responses of hypoxia depicted in Figure 1 are result of the alterations in expression of these proteins.

Hypoxia regulators

Activation of transcription factors is one of the rapid cellular events that take place in response to cellular stress caused by hypoxia. Heat shock factor-1 (HSF-1) and HIF-1 represent two separate classes of transcription factors that are specifically and rapidly activated in response to cellular stress [39,40].

HIF-1: HIF-1 is the key molecule involved in hypoxia. It is a heterodimeric complex composed of HIF-1 α and HIF-1 β subunits. The dimer binds to specific DNA enhancer sequences and regulates the expression of target genes. Both HIF-1 α and HIF-1 β are constitutively expressed under normal oxygen conditions (normoxia), however, HIF-1 α gets quickly degraded before its dimerization with HIF-1 β [41]. Normoxic HIF-1 α degradation is mediated by a series of hydroxylations and ubiquitinations that tag HIF-1 α for disposal through proteosomes [42,43]. Following a shift to low oxygen environment, the α -subunit gets stabilized and translocates to nucleus. HIF-1 α has an oxygen-dependent domain (ODD) that is important for regulation of its stability. Under normoxic conditions the ODD is recognized by the product of Von Hippel Lindau (pVHL) suppressor gene, a component of a multisubunit ubiquitin-protein ligase complex that tags the subunit with polyubiquitin to promote HIF-degradation. When the cells are exposed to hypoxia, pVHL fails to recognize HIF-1 α , allowing its accumulation and subsequent transportation to nucleus. Once in nucleus, HIF-1 α dimerizes with HIF-1 β and regulates




Figure 4a: Hypoxia-inducible gene regulation by HIF- α . In normoxia, HIF- α is transcriptionally inactive and is rapidly degraded by the ubiquitin (Ub) proteasome pathway. In hypoxia, HIF- α undergoes protein stabilization and translocation from the cytoplasm to the nucleus, where it dimerizes with HIF- β to induce the transcription of related genes.




Figure 4b: Stabilization of HIF- α by pVHL protein. (+) shows recognition of ODD by pVHL and (-) shows failure of recognition of ODD by pVHL.

the expression of hypoxia-inducible genes [44,45] (Figures 4a and 4b). HIF networking [45] and HIF-1 biology in hypoxic adaptation [46] is well understood at present. A very recent finding showed the involvement of insulin in regulation of HIF-1 α through a novel transcriptional mechanism by a ROS sensitive activation of Sp1 in 3T3-L1 preadipocyte. Insulin increases HIF-1 α promoter activity. In this study mutation analyses, electrophoretic mobility shift assay and chromatin immunoprecipitation assay confirmed the role of Sp1 in HIF-1 α transcription [47].

HIF-2: HIF-2 is closely related to HIF-1 and both are related key transcriptional regulators of hypoxic response [48]. Preferential binding of HIF-2 α to HRE (hypoxia responsive elements) at the *Epo* (erythropoietin) locus has been proposed by Ratcliffe [49]. While HIF-1 α binds to isolated HRE, HIF-2 α binds preferentially at the HRE within the native *Epo*3' enhancer. Similar to HIF-1 α , HIF-2 α also escapes proteolysis during low oxygen condition and dimerizes with HIF-1 β , recruits coactivators, and activates transcription via HREs [49]. Recently it has been reported that HIF-2 require another regulatory factor, the upstream stimulatory factor 2 (USF2), for hypoxic transcriptional response, for activation of HIF-2 target genes [50]. This suggests that HIF-2 also has also regulatory effect on hypoxia responsive gene. However, the role of HIF-1 has been more explored as key regulator of hypoxia than HIF-2. It's another isoform, HIF-3 is also reported which is a distantly related isoform generated by alternate splicing and encodes for a polypeptide that antagonizes HRE-dependent gene expression [49].

Heat shock factor-1 (HSF-1): Heat shock factor-1 (HSF-1) is important for the induction of heat shock proteins (HSPs) such as HSP-27, and HSP-70 which in turn act as chaperones preventing the aggregation and inactivation of essential cellular proteins [39]. HSPs




Figure 3: Overview of steps involved in proteomic analysis.

Classification	Proteins	Physiological function	References
Proteins of energy metabolism including	Glycolytic enzymes	Often referred as hypoxia-associated proteins (HAPs), these proteins include the glycolytic enzyme GAPDH and non-neuronal enolase unique to endothelial cells. Expression of these proteins helps in up regulated tolerance and adaptation to lack of oxygen. This may be one of the mechanisms to overcome the ischemic injury during hypoxia. Increased expression of heat shock proteins have been found in hypoxic condition.	[27,73,74]
Stress related proteins	Heat shock Proteins (HSPs)	The enhanced synthesis and accumulation of several functionally and compartmentally distinct families of HSPs, such as HSP70, HSP90, HSP60, and HSP27 is one of the cellular mechanisms for protection against the stress induced by environmental cues. Inflammatory responses during hypoxia are due to over expression of these proteins.	[75,12,76]
Membrane-bound proteins that include transporters and receptors	Acid-base transporters, glucose transporter	The influence of intermittent hypoxia exposure on the expression of acid-base transporters in the mouse central nervous system, especially in the cerebellum is the decreased expression of sodium/hydrogen exchanger (NHE) isoform 1 and sodium-bicarbonate co-transporter. Edema of CNS due to hypoxia is related to alteration in these proteins.	[77-79]
Cytosolic proteins	Antioxidants, signalling cascade proteins	The expression of antioxidants and the proteins associated with signalling cascade is altered in hypoxia. The expression of nitric oxide synthase (NOS) endothelial (eNOS) and inducible (iNOS) forms is increased during hypoxic condition. Overexpression of NOS leads to vasodilation to minimise the effect of hypoxia.	[80-82]

Table 2: Categorization of hypoxia evoked proteins.

are vital in maintaining cellular homeostasis and are up-regulated during hypoxic condition [12]. In unstressed cells, HSF-1 binds to HSP-90 and remains in inactive form. During cellular stress, HSF-1 rapidly dissociates from HSP-90, gets trimerized and is translocated to the nucleus, where it activates the transcription of genes that contain the characteristic heat shock response element such as HSP-27 and HSP-70 thereby regulating hypoxia [51-52]. Induction of the heat shock pathway during hypoxia is also dependent on HIF-1 [53]. Recently it has been reported that HSF-1 is involved in hypoxic tumour progression via regulation of HIF-1 [54].

Erythropoietin (EPO): Erythropoietin is required for the proliferation and differentiation of erythroid progenitor cells to yield RBCs. Its response is elicited in a number of tissues, depending on level of expression of its receptor (EPOR). During low oxygen tension HIF-1 binds to hypoxia response elements and activates the transcription of EPO and other hypoxia-responsive genes [55-56]. The EPOR expression and the biological response to EPO have been observed in endothelial, neuronal, muscle, cardiac and certain other cell types [57]. In neuronal cells, EPORs are induced by hypoxia resulting in increased EPO response due to its binding to EPORs [58]. EPO maintains several activities in cardiovascular system; the induction of NO production by EPO mediated cascade under hypoxic conditions provides one of the explanations for the protection conferred by EPO in myocardial infarction as it may rapidly increase vasodilatation and facilitate effective collateral circulation [59]. Hypoxic-stimulated enhanced erythropoietin secretion is also reported in mice [56]. The regulation of EPO through HIFs has been recently reviewed [60].

Vascular endothelial growth factor (VEGF) is an important growth and permeability factor for endothelial cells and is expressed in lungs at high level. Hypoxia is a potent inducer of VEGF gene expression. The regulation takes place at transcriptional level through activation of HIF-1 α and HIF-2 α that bind to response element in VEGF gene. In alveolar epithelial cells, hypoxia induces an up-regulation of VEGF mRNA transcripts due to transcriptional activation of VEGF gene without any change in mRNA stability [61]. There are strong evidences to suggest that HIF plays a major role in hypoxia-induced VEGF regulation of VEGF gene expression modulates epithelial cell proliferation and surfactant protein expression [62]. However, the precise role of increased VEGF secretion in overall adaptation process of alveolar epithelial cells in response to hypoxia remains to be fully elucidated. Rehn et al. [63] have reported the hypoxia induced VEGF regulation of murine hematopoietic stem cell function.

Mitochondrial autophagy: Reactive oxygen species serve as signalling molecules at low level but at high level these damage cell organelles [64]. The most severe response and mechanism during hypoxic adaptation is mitochondrial autophagy due to ROS formation. Mitochondrial autophagy is necessary to protect cell against oxidative stress [65-66]. This process requires HIF-1 dependent expression of BNIP3 (BNIP3 is a pro-apoptotic BH3-only protein which is associated with mitochondrial dysfunction and cell death) and the constitutive expression of Beclin-1 and Atg5 (both are regulators of autophagy) [67-68]. In cells subjected to prolonged hypoxia, mitochondrial autophagy has been found to be an adaptive metabolic response which is necessary to prevent increased ROS levels and cell death [69].

The roles of all these proteins in hypoxia have been well established. These are regarded as classical regulators of hypoxia associated genes.

HIF-independent hypoxia regulation

As discussed HIF-1 and Pur- α are the identified regulators of hypoxia. Hypoxia leads to inflammation and binding of circulating leukocytes to endothelium with resultant induction of hypoxia-responsive genes. Such binding is mediated by monocytes that directly sense hypoxic conditions and respond by inducing expression of the β -2 integrin family of adhesion molecules. Earlier it was thought that induction of β -2 integrin is dependent on HIF-1 [70], however, later studies reported that induction of β -2 integrin can also take place in HIF-1 independent manner through Pur- α . Pur- α binds to HIF-1 independent β -2 integrin promoters under hypoxic condition. Mutagenesis in Pur- α binding site abolishes the ability of the promoters to respond to hypoxia [71]. The role of Pur- α need to be studied further. Recently a hypoxic study on *Drosophila melanogaster* provided evidences that HIF and non-HIF dependent pathways are complemented by the action of estrogen-related receptor [72]. Surprisingly, the results of this study emphasized more prominent role of HIF-independent pathways than previously thought.

Categorization of hypoxia evoked proteins

Proteins which are altered in hypoxic condition have been classified into different groups depending on their activities (Table 2).

Many of these proteins are altered as the result of multiple environmental/pathological conditions and lack specificity. However relatively fewer proteomic based studies have been carried out using for identification of novel protein(s) associated with high altitude adaptation/HH. Hypoxia affects tissues whose function relies on

oxygen metabolism or transport. This includes skeletal muscles where energy metabolism is activity dependent and enhanced by a magnitude with onset of contraction. A study carried out on comparative profile of skeletal muscle proteome of human volunteer natives of Tibet (HA) and lowlanders reported seven differentially expressed proteins [83]. It was found that glutathione-S-transferase P1-1, Δ^2 -enoyl-CoA-hydratase, phosphoglycerate mutase, and myoglobin were significantly overexpressed while NADH-ubiquinone oxidoreductase was only slightly overexpressed in highlanders. On the other hand, glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase were slightly down-regulated in highlanders. From this study it became clear that hypoxia affects energy metabolism pathways. The result of a similar study state that hypoxic induction and reoxygenation of primary human hepatocytes induce proteome changes in protein associated with of glucose metabolism, oxidative protection and peroxisomal function [84]. It has been reported that exposure to hypoxia results in reduced skeletal muscle mass [85,86]. At the cellular level the alterations include reduction in number as well as size of mitochondrial volume density and accumulation of lipofuscin, a product of lipid peroxidation. Differential analysis has indicated that proteins involved in iron transport, TCA cycle, oxidative phosphorylation, and oxidative stress responses are significantly decreased in hypoxia. Hypoxia markers such as HIF-1 α and pyruvate dehydrogenase kinase 1 (PDK1) remained unaltered [87]. Another acute vs. chronic hypoxia study reports that repeated acute hypoxic exposure have the potential to slow down muscle atrophy and even to stimulate muscle mass accretion when coupled to resistance exercise as is the case with occlusion training [88]. Recently it has been found that chronic hypobaric hypoxia (CHH) increases fast-twitch and slow-twitch limb muscle force and fatigue in rats [89]. The analysis of lung proteome during pulmonary arterial hypertension (PAH, which is a common manifestation of sudden HA exposure) in male Sprague-Dawley rats showed differential expression of HSP27, septin 2, tropomyosin β -chain, annexin 3, HSP70, F-actin capping protein, biliverdin reductase and ERp29 (an endoplasmic reticulum protein) in PAH as compared to controls (without PAH) [89]. In another proteomic study conducted on patients with idiopathic PAH it was found that 25 proteins were differentially expressed in lung [12]. These include chloride intracellular protein1, annexin A3, phosphoglucomutase-like protein 5, and serum deprivation-response protein. These proteins could be associated with cell growth, proliferation, intracellular trafficking and signalling pathways. The changes in some of these proteins have been validated by Western blotting. The validated proteins include periostin, haptoglobin and chloride intracellular channel protein 1 (CLIC-1) and chloride intracellular channel protein 4 (CLIC-4) [13]. Acute hypoxia also induces apoptosis of pancreatic β -cells by activation of the unfolded protein response and upregulation of CHOP (C/EBP homologous protein) which is a pro-apoptotic transcription factor, indicating insulin metabolism impairment that ultimately results in altered energy metabolism [69]. In another report it was found that chronic intermittent hypoxia (CIH) and chronic sustained hypoxia (CSH) differentially regulate left ventricular inflammatory and extracellular matrix responses. The levels of matrix metalloprotein (MMP-9) and fibronectin are lowered in CIH, suggesting decreased inflammatory status whereas in case of CSH extracellular matrix and adhesion molecule were found to be up regulated indicating an increased inflammation during CSH [90]. Another study reports an increase in cysteine oxidation in endothelial cells in response to acute hypoxia which could be reversed by reoxygenation [91]. Surprisingly, humoral immune system modulation was also observed following single and repeated exposure to hypoxia in Eurasian perch [91]. In a

recent study on comparison of human plasma proteome between sea level and high altitude natives it was reported that there is alteration in number of anti inflammatory proteins in highlanders [14]. The up-regulated proteins are vitamin D-binding protein, hemopexin, alpha-1-antitrypsin, haptoglobin b-chain; apolipoprotein A1, transthyretin and hemoglobin b-chain, the down-regulated proteins are transferrin, complement C3, serum amyloid, complement component 4A and plasma retinol binding protein. These results show that the adaptive mechanism sustains the inflammation balance in HA natives exposed to HH. Another exploratory proteomic analysis of human volunteers under hypobaric hypoxia and acute mountain sickness showed the abundance of antioxidant proteins such as peroxiredoxin 6, glutathione peroxidase and sulfhydryl oxidase [15]. Hypoxia is present in most solid tumors and is clinically correlated with increased metastasis and poor patient survival. A very recent, in situ hypoxia proteome study on tumor samples presents idea of more than 100 proteins that are found to differentially expressed [92].

All these findings suggest that different cellular responses are evoked in different organs under hypoxic condition (either due to disease or altitude) that lower its ill effect, failure of which leads to serious complications. The hypoxic adaptation involves simultaneous modulation of a number of different pathways. More studies are needed to understand the precise role of these responses and their coordination during hypoxic adaptation.

Prospective biomarkers for high altitude adaptation

A biomarker can be defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [93]. Biomarkers are key indicator for molecular or cellular events that link the exposure to specific environmental condition with health. These play important role in understanding the relationship between exposure to environmental chemicals, the development of chronic human diseases, and the identification of subgroups that are at increased risk for disease. Much progress has been made in identifying and validating new biomarkers that can be used in diagnosis and prognosis of certain life threatening diseases. Some of the proteins which can be prospective biomarkers for high altitude adaptation are discussed below. These proteins show marked altered expression during hypoxic exposure.

Pur- α : Pur- α is a transcriptional activator protein that has been implicated as a novel hypoxia response factor. It is responsible for coordinated induction of β -2 integrin family of adhesion molecules [71]. Increased abundance of Pur- α has also been found in lungs of the patient with idiopathic PAH [13]. Pur- α expression leads to increased angiogenesis.

Chloride intracellular channel protein-4: CLIC-4 has been reported to have role in angiogenesis by supporting the acidification of vacuoles along the intracellular tubulogenic pathway [94]. Increased CLIC-4 expressions was found in human pulmonary artery endothelial cells in PAH that may play a role in pathogenesis of PAH patients and provide novel insights into disease pathogenesis and treatment strategies [13].

Periostin: Periostin is a TGF- β inducible, 90-kDa protein that advances the atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis. Up-regulation of this protein has also been reported in patients with idiopathic PAH [13]. Periostin mediates the increased pro-angiogenic activity of gastric cancer cells under hypoxic conditions [95].

Macrophage migration inhibitory factor (MIF): It has been reported that hypoxia stimulates the expression of MIF in human vascular smooth muscles via HIF- α dependent pathway [96]. In this study the expression of both, the MIF mRNA and protein both found to be up-regulated as early as 2 hours after cultured human VSMCs were exposed to moderate hypoxic condition (3-10% O₂). MIF has also been found to be one of the mediators of hypoxia-induced pulmonary hypertension [97].

HSP-70: Preinduction of HSP-70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain up-regulation of HSP-70 has also been reported in lung tissues of male Sprague-Dawley rats after induction of PAH [12]. HSP-70 protects intestinal epithelial cells from hypoxia/reoxygenation injury via a mechanism involving mitochondrial pathways [98].

Rho-A: Hypoxia activates Rho-A and subsequently Rho-A kinase activity [99]. It has been reported that prolonged hypoxia increases Rho-A and ROS signaling and activation in pulmonary artery smooth muscles and endothelial cells [100]. Under hypoxic condition, RhoA activation promotes VEGF secretion which has a prominent role in hypoxia [101]. However, the mechanism by which Rho-A is activated during hypoxia is not well established.

p53 and hypoxia

The tumor suppressor activity of p53 is well documented. Its expression is induced by hypoxia. The expression and activity of p53 under hypoxia bears relationship to tumor inducing action of mutated p53, as the microenvironment in tumor tissue is hypoxic [102,103]. Earlier studies have demonstrated an indirect interaction between p53 and HIF-1 α , probably through MDM2 [104]. However, in a later study evidences were presented for direct interaction between p53 and HIF-1 α . Two p53-binding sites have been identified within the oxygen dependent degradation domain of HIF-1 α , suggesting that one molecule of HIF-1 α interacts with one p53 dimer [105]. Recent studies have shown that hypoxia-mediated p53 activation is through the ATR-Chk1-MDMX-14-3-3 γ signaling pathway [106]. Hypoxia activates ATR and then Chk1, which in turn phosphorylates MDMX at S367, suppressing its activity and activating p53 [106]. It has been found that wild type p53 rescues mutated p53 and leads to hypoxic tumor regression [68]. This novel role of wild type p53 as molecular chaperone raises the possibility that p53 self-rescue may be involved in reversing the oncogenic function of mutated p53 in cancer cells. Further, it has been shown that there is a novel chaperone-like activity that resides in p53 N-terminal domain. This study might have significance in understanding the role of p53 NTD in its self stabilization, conformational activation and apoptosis under heat-stress conditions [107]. Although the chaperone and apoptotic potential of wild type p53 are comparable with that of NTD, the tumor regression potential of NTD is about one half of wild type p53 which suggests that additional *in vivo* p53-bound modulating factors may also be involved in tumor regression [106]. The properties of p53 and further understanding of the relationship between p53 and HIF may provide new insight into both hypoxic adaptation and cancer therapy.

Conclusion and Future Prospects

Hypoxia is a generalised term referring to low oxygen condition. The high altitude hypoxia can not be completely separated as a pathological condition either from hypoxia due to cellular toxicity or a disease. Studies have shown that there are marked differences between genetics, proteomics and physiology among high land residents and low land

residents. People who fall in between the i.e. those who ascends to HA regions necessarily face sickness ranging from altitude sickness to either normalization or turning into more serious conditions like HAPE, HACE etc. Proteomics has been helpful in understanding the role of differentially expressed proteins. Hypoxia affects a number of cellular processes and has been recognized as the major contributing factor in a variety of pathological and physiological processes. Single or whole proteome analysis of expression and posttranslational modifications of proteins in response to hypoxia have revealed that complex interplay of molecules takes place in multiple cellular compartments that helps the cell in coping with reduced oxygen availability for cellular functions. During hypoxia, the genes involved in various physiological processes such as metabolism, signal transduction, transcription, apoptosis, cell cycle and ubiquitination pathways are differentially expressed. Several proteins have been identified and categorised, however, the precise role of many these proteins is not fully understood. Proteomics provides new directions for better understanding of cellular mechanisms associated with the response and adaptation to hypoxia. Further, some of the proteins which are only indirectly related to hypoxia may also prove to be important candidate biomarker for HH. Hypoxic condition, whether due to some pathological condition (diseases) or physiological changes (altitude), cannot be distinguished completely from each other and therefore the proteins found to be altered under one condition will have role under other condition also. At present genomic profiling related to high altitude adaptation and sickness is much ahead of proteomic findings. It is therefore relevant to focus on hypoxia proteomics to find newer proteins and relate them with existing one to get better understanding of unique mechanism of adaptation. Such studies will also have implications in better management of hypoxia related health problems.

Acknowledgement

Kumari Smita thanks ICMR for financial assistance in the form of a research fellowship.

References

1. Beall CM, Decker MJ, Brittenham GM, Kushner I, Gebremedhin A, et al. (2002) An Ethiopian pattern of human adaptation to high-altitude hypoxia. Proc Natl Acad Sci USA 99: 17215-17218.
2. Scheinfeldt LB, Soi S, Thompson S, Ranciaro A, Woldemeskel D, et al. (2012) Genetic adaptation to high altitude in the Ethiopian highlands. Genome Biol 13: R1.
3. Alkorta-Aranburu G, Beall CM, Witonsky DB, Gebremedhin A, Pritchard JK, et al. (2012) The genetic architecture of adaptations to high altitude in Ethiopia. PLoS Genet 8: e1003110.
4. Ward MP, Milledge JS, West JB (2002) High Altitude Physiology and Medicine (3rd Edn) Arnold, London.
5. Moore LG, Shriver M, Bemis L, Hickler B, Wilson M, et al. (2004) Maternal adaptation to high-altitude pregnancy: an experiment of nature—a review. Placenta 25 Suppl A: S60-71.
6. De Hart RL, Davis JR (2002) Fundamentals of Aerospace Medicine. (3rd Edn) Lippincott, Williams and Wilkins, Philadelphia.
7. Rainford DJ, Gradwell DP (2006) Ernsting's Aviation Medicine. (4th Edn) Hodder Arnold, London.
8. Paralakar SJ, Paralakar JH (2010) High-altitude medicine. Indian J Occup Environ Med 14: 6-12.
9. Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49 Suppl 2: 129S-48S.
10. Wilber RL (2007) Application of altitude/hypoxic training by elite athletes. Med Sci Sports Exerc 9: 1610-1624.
11. Johnson PL, Edwards N, Burgess KR, Sullivan CE (2010) Sleep architecture changes during a trek from 1400 to 5000 m in the Nepal Himalaya. J Sleep

- Res 19: 148-156.
12. Laudi S, Steudel W, Jonscher K, Schöning W, Schniedewind B, et al. (2007) Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. *Proteomics* 7: 2469-2478.
13. Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, et al. (2010) Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. *Circulation* 122: 2058-2067.
14. Ahmad Y, Sharma NK, Garg I, Ahmad MF, Sharma M, et al. (2013) An insight into the changes in human plasma proteome on adaptation to hypobaric hypoxia. *PLoS One* 8: e67548.
15. Julian CG, Subudhi AW, Hill RC, Wilson MJ, Dimmen AC, et al. (2014) Exploratory proteomic analysis of hypobaric hypoxia and acute mountain sickness in humans. *J Appl Physiol* (1985) 116: 937-944.
16. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. *PLoS Med* 3: e47.
17. Barman SA (2007) Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. *Am J Physiol Lung Cell Mol Physiol* 293: L472-479.
18. Geiger K, Leiberer A, Muendlein A, Stark N, Geller-Rhomberg S, et al. (2011) Identification of hypoxia-induced genes in human SGBS adipocytes by microarray analysis. *PLoS One* 6: e26465.
19. Semenza GL (1999) Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol* 15: 551-578.
20. Wenger RH (2002) Cellular adaptation to hypoxia: O₂-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O₂-regulated gene expression. *FASEB J* 16: 1151-1162.
21. Varshavsky A (1996) The N-end rule: functions, mysteries, uses. *Proc Natl Acad Sci U S A* 93: 12142-12149.
22. Gygi SP, Rochon Y, Franz A, Aebersold R (1999) Correlation between protein and mRNA abundance in yeast. *Mol Cell Biol* 19: 1720-1730.
23. Davidson P, Paulson L, Hesse C, Blennow K, Nilsson CL (2001) Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. *Proteomics* 1: 444-452.
24. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, et al. (1999) Direct analysis of protein complexes using mass spectrometry. *Nat Biotechnol* 17: 676-682.
25. Spahr CS, Susin SA, Bures EJ, Robinson JH, Davis MT, et al. (2000) Simplification of complex peptide mixtures for proteomic analysis: reversible biotinylation of cysteinyl peptides. *Electrophoresis* 21: 1635-1650.
26. Liu B, Marks JD (2000) Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. *Anal Biochem* 286: 119-128.
27. Davidsson P, Nilsson CL (1999) Peptide mapping of proteins in cerebrospinal fluid utilizing a rapid preparative two-dimensional electrophoretic procedure and matrix-assisted laser desorption/ionization mass spectrometry. *Biochim Biophys Acta* 1473: 391-399.
28. Herbert B, Harry E (2003) *Two-Dimensional Electrophoresis Protocols*. Springer, Australia.
29. Strupat K (2005) Molecular weight determination of peptides and proteins by ESI and MALDI. *Methods Enzymol* 405: 1-36.
30. Christin C, Bischoff R, Horvatovich P (2011) Data processing pipelines for comprehensive profiling of proteomics samples by label-free LC-MS for biomarker discovery. *Talanta* 83: 1209-1224.
31. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM (2008) Applications of SELDI-MS technology in oncology. *J Cell Mol Med* 12: 1535-1547.
32. Mayne J, Starr AE, Ning Z, Chen R, Chiang CK, et al. (2014) Fine tuning of proteomic technologies to improve biological findings: advancements in 2011-2013. *Anal Chem* 86: 176-195.
33. Thomas SN, Liao Z, Clark D, Chen Y, Samadani R, et al. (2013) Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer. *Proteomes* 1: 87-108.
34. Taylor DD, Gerçel-Taylor C (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. *Br J Cancer* 92: 305-311.
35. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, et al. (2013) Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. *Proc Natl Acad Sci U S A* 110: 7312-7317.
36. Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, et al. (2011) Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. *Proc Natl Acad Sci USA* 108: 13147-13152.
37. Shteynberg D, Nesvizhskii AI, Moritz RL, Deutsch EW (2013) Combining results of multiple search engines in proteomics. *Mol Cell Proteomics* 12: 2383-2393.
38. Morimoto RI (1998) Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. *Genes Dev* 12: 3788-3796.
39. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. *Crit Rev Biochem Mol Biol* 35: 71-103.
40. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A* 92: 5510-5514.
41. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-1alpha to the von Hippel-Lindau ubiquitination complex by O₂-regulated prolyl hydroxylation. *Science* 292: 468-472.
42. Bruck RK (2003) Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. *Genes Dev* 17: 2614-2623.
43. Ziegler JE, Jovin IS, Huang Y (2007) Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale J Biol Med* 80: 51-60.
44. Greer SN, Metcalf JL, Wang Y, Ohm M (2012) The updated biology of hypoxia-inducible factor. *EMBO J* 31: 2448-2460.
45. Cavadas MA, Nguyen LK, Cheong A (2013) Hypoxia-inducible factor (HIF) network: insights from mathematical models. *Cell Commun Signal* 11: 42.
46. Biswas S, Mukherjee R, Tapryal N, Singh AK, Mukhopadhyay CK (2013) Insulin regulates hypoxia-inducible factor-1 α transcription by reactive oxygen species sensitive activation of Sp1 in 3T3-L1 preadipocyte. *PLoS One* 8: e62128.
47. Bracken CP, Fedele AO, Linke S, Balrak W, Lisy K, et al. (2006) Cell-specific regulation of hypoxia-inducible factor (HIF)-1 α and HIF-2 α stabilization and transactivation in a graded oxygen environment. *J Biol Chem* 281: 22575-22585.
48. Ratcliffe PJ (2007) HIF-1 and HIF-2: working alone or together in hypoxia? *J Clin Invest* 117: 862-865.
49. Pawlusz MR, Wang L, Ware K, Hu CJ (2012) Upstream stimulatory factor 2 and hypoxia-inducible factor 2 α (HIF2 α) cooperatively activate HIF2 target genes during hypoxia. *Mol Cell Biol* 32: 4595-4610.
50. Shi Y, Mosser DD, Morimoto RI (1998) Molecular chaperones as HSF1-specific transcriptional repressors. *Genes Dev* 12: 654-666.
51. Morano KA, Thiele DJ (1999) Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. *Gene Expr* 7: 271-282.
52. Baird NA, Turnbull DW, Johnson EA (2006) Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1. *J Biol Chem* 281: 38675-38681.
53. Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, et al. (2012) Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. *Mol Cell Biol* 32: 929-940.
54. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, et al. (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. *Blood* 104: 2073-2080.
55. Martinez MP, Conti MI, Ana C, Barcelo AC, Bozzini EC (2010) Hypoxia-Stimulated Erythropoietin Secretion in Mice with Different Types of Induced Polycythemia: The Posthypoxic Enigma. *Advanced Studies in Biology* 2: 35-52.

56. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, et al. (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. *J Biol Chem* 275: 39754-39761.
57. Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, et al. (2000) Production and processing of erythropoietin receptor transcripts in brain. *Brain Res Mol Brain Res* 81: 29-42.
58. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, et al. (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. *Proc Natl Acad Sci U S A* 100: 11612-11617.
59. Haase VH (2013) Regulation of erythropoiesis by hypoxia-inducible factors. *Blood Rev* 27: 41-53.
60. McClintock DS, Santore MT, Lee VY, Brunelle J, Budinger GR, et al. (2002) Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. *Mol Cell Biol* 22: 94-104.
61. Clerici C, Planès C (2009) Gene regulation in the adaptive process to hypoxia in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 296: L267-274.
62. Rehn M, Olsson A, Reckzeh K, Diffner E, Carmeliet P, et al. (2011) Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche. *Blood* 118: 1534-1543.
63. de Magalhães JP, Church GM (2006) Cells discover fire: employing reactive oxygen species in development and consequences for aging. *Exp Gerontol* 41: 1-10.
64. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, et al. (2006) Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. *J Biol Chem* 281: 13957-13963.
65. Mathew R, White E (2011) Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger. *Cold Spring Harb Symp Quant Biol* 76: 389-396.
66. Kang R, Zeh HJ, Lotze MT, Tang D (2011) The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* 18: 571-580.
67. Lee JH, Jin Y, He G, Zeng SX, Wang YV, et al. (2012) Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3 γ inactivation of MDMX protein. *J Biol Chem* 287: 20898-20903.
68. Zhang K, Zhao T, Huang X, Liu ZH, Xiong L, et al. (2009) Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. *Cell Stress Chaperones* 14: 407-415.
69. Kong T, Eltzschig HK, Karhausen J, Colgan SP, Shelley CS (2004) Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. *Proc Natl Acad Sci U S A* 101: 10440-10445.
70. Kong T, Scully M, Shelley CS, Colgan SP (2007) Identification of Pur alpha as a new hypoxia response factor responsible for coordinated induction of the beta 2 integrin family. *J Immunol* 179: 1934-1941.
71. Li Y, Padmanabha D, Gentile LB, Dumur CI, Beckstead RB, et al. (2013) HIF- and non-HIF-regulated hypoxic responses require the estrogen-related receptor in *Drosophila melanogaster*. *PLoS Genet* 9: e1003230.
72. Webster KA (2003) Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. *J Exp Biol* 206: 2911-2922.
73. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. *Mol Cancer Ther* 6: 732-741.
74. Oehler R, Schmierer B, Zellner M, Prohaska R, Roth E (2000) Endothelial cells downregulate expression of the 70 kDa heat shock protein during hypoxia. *Biochem Biophys Res Commun* 274: 542-547.
75. Zhang Y, Dong Y, Wu X, Lu Y, Xu Z, et al. (2010) The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. *J Biol Chem* 285: 4025-4037.
76. Douglas RM, Xue J, Chen JY, Haddad CG, Alper SL, et al. (2003) Chronic intermittent hypoxia decreases the expression of Na/H exchangers and HCO₃-dependent transporters in mouse CNS. *J Appl Physiol* (1985) 95: 292-299.
77. Mobasher A, Richardson S, Mobasher R, Shakibaei M, Hoyland JA (2005) Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: Putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. *Histol Histopathol* 20: 1327-1338.
78. Herbert A, Ng H, Jessup W, Kockx M, Cartland S, et al. (2011) Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. *Br J Dermatol* 164: 308-315.
79. Le Cras TD, Xue C, Rengasamy A, Johns RA (1996) Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. *Am J Physiol* 270: L164-170.
80. Fagan KA, Morrissey B, Fouty BW, Sato K, Harral JW, et al. (2001) Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension. *Respir Res* 2: 306-313.
81. Strijdom H, Friedrich SO, Hattingh S, Chamane N, Lochner A (2009) Hypoxia-induced regulation of nitric oxide synthase in cardiac endothelial cells and myocytes and the role of the PI3-K/PKB pathway. *Mol Cell Biochem* 321: 23-35.
82. Gelfi C, De Palma S, Ripamonti M, Eberini I, Wait R, et al. (2004) New aspects of altitude adaptation in Tibetans: a proteomic approach. *FASEB J* 18: 612-614.
83. Strey CW, Gestrich J, Beckhaus T, Marquez-Pinilla RM, Oppermann E, et al. (2010) Hypoxia and reoxygenation of primary human hepatocytes induce proteome changes of glucose metabolism, oxidative protection and peroxisomal function. *Int J Mol Med* 4: 577-584.
84. Gelfi C, De Palma S, Ripamonti M, Eberini I, Wait R, et al. (2004) New aspects of altitude adaptation in Tibetans: a proteomic approach. *FASEB J* 18: 612-614.
85. Mason S, Johnson RS (2007) The role of HIF-1 in hypoxic response in the skeletal muscle. *Adv Exp Med Biol* 618: 229-244.
86. Viganò A, Ripamonti M, De Palma S, Capitanio D, Vasso M, et al. (2008) Proteins modulation in human skeletal muscle in the early phase of adaptation to hypobaric hypoxia. *Proteomics* 8: 4668-4679.
87. Deldicque L, Francaux F (2013) Acute vs. chronic hypoxia: What are the consequences for skeletal muscle mass? *Cellular and Molecular Exercise Physiology* 2: e5.
88. El-Khoury R, Bradford A, O'Halloran KD (2012) Chronic hypobaric hypoxia increases isolated rat fast-twitch and slow-twitch limb muscle force and fatigue. *Physiol Res* 61: 195-201.
89. Zhang K, Zhao T, Huang X, Liu ZH, Xiong L, et al. (2009) Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. *Cell Stress Chaperones* 14: 407-415.
90. Ramirez TA, Jourdan-Le Saux C, Joy A, Zhang J, Dai Q, et al. (2012) Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. *Hypertens Res* 35: 811-818.
91. Izquierdo-Alvarez A, Ramos E, Villanueva J, Hernansanz-Agustín P, Fernández-Rodríguez R, et al. (2012) Differential redox proteomics allows identification of proteins reversibly oxidized at cysteine residues in endothelial cells in response to acute hypoxia. *J Proteomics* 17: 5449-5462.
92. Douxfils J, Deprez M, Mandiki SN, Milla S, Henrotte E, et al. (2012) Physiological and proteomic responses to single and repeated hypoxia in juvenile Eurasian perch under domestication-clues to physiological acclimation and humoral immune modulations. *Fish Shellfish Immunol* 33: 1112-1122.
93. Djidja MC, Chang J, Hadjiropocis A, Schmich F, Sinclair J, et al. (2014) Identification of hypoxia-regulated proteins using MALDI-mass spectrometry imaging combined with quantitative proteomics. *J Proteome Res* 13: 2297-2313.
94. Glassman RH, Ratain MJ (2009) Biomarkers in early cancer drug development: limited utility. *Clin Pharmacol Ther* 85: 134-135.
95. Ulmasov B, Bruno J, Gordon N, Hartnett ME, Edwards JC (2009) Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. *Am J Pathol* 174: 1084-1096.
96. Qiu F, Shi CH, Zheng J, Liu YB (2013) Periostin mediates the increased pro-angiogenic activity of gastric cancer cells under hypoxic conditions. *J Biochem Mol Toxicol* 27: 364-369.
97. Fu H, Luo F, Yang L, Wu W, Liu X (2010) Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vascular smooth muscle cells via HIF-1 α dependent pathway. *BMC Cell Biol* 11: 66.
98. Zhang Y, Talwar A, Tsang D, Bruchfeld A, Sadoughi A, et al. (2012) Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. *Mol Med* 18: 215-223.

99. Zhang Y, Dong Y, Wu X, Lu Y, Xu Z, et al. (2010) The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. *J Biol Chem* 285: 4025-4037.
100. Barman SA (2007) Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. *Am J Physiol Lung Cell Mol Physiol* 293: L472-479.
101. Chi AY, Waypa GB, Mungai PT, Schumacker PT (2010) Prolonged hypoxia increases ROS signaling and RhoA activation in pulmonary artery smooth muscle and endothelial cells. *Antioxid Redox Signal* 12: 603-610.
102. Ma J, Zhao Q, Ren H, Liu W, Xue Y (2012) Role of RhoA in hypoxia-induced breast cancer cell VEGF secretion and proliferation, migration and tube formation of HUVECs. *Nan Fang Yi Ke Da Xue Xue Bao* 32: 784-788.
103. Zhao Y, Chen XQ, Du JZ (2009) Cellular adaptation to hypoxia and p53 transcription regulation. *J Zhejiang Univ Sci B* 10: 404-410.
104. Chen D, Li M, Luo J, Gu W (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. *J Biol Chem* 278: 13595-13598.
105. Fels DR, Koumenis C (2005) HIF-1alpha and p53: the ODD couple? *Trends Biochem Sci* 30: 426-429.
106. Gogna R, Madan E, Kuppusamy P, Pati U (2012) Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression. *J Biol Chem* 287: 2907-2914.
107. Sharma NK, Sethy NK, Meena RN, Ilavazhagan G, Das M, et al. (2011) Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. *Peptides* 32: 1217-1224.

This article was originally published in a special issue, **Proteomics Technologies** handled by Editor(s). Dr. Jie Luo, Institute for Systems Biology, Seattle WA, USA